B of A Securities Maintains Underperform on Fulcrum Therapeutics, Raises Price Target to $7
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Tazeen Ahmad maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Underperform and raises the price target from $6 to $7.
B of A Securities analyst Tazeen Ahmad maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Underperform and raises the price target from $6 to $7.